| S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials | |
| Zhong, Sheng; Qie, Shuai; Yang, Liu; Yan, Qi; Ge, Linna; Wang, Zhongfeng | |
| 刊名 | MEDICINE
 |
| 2017 | |
| 卷号 | 96期号:30 |
| 关键词 | advanced pancreatic cancer combination therapy irinotecan leucovorin monotherapy oxaliplatin S-1 second-line chemotherapy |
| ISSN号 | 0025-7974 |
| URL标识 | 查看原文 |
| 语种 | 英语 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/3539871 |
| 专题 | 吉林大学白求恩第一医院 |
| 推荐引用方式 GB/T 7714 | Zhong, Sheng,Qie, Shuai,Yang, Liu,et al. S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials[J]. MEDICINE,2017,96(30). |
| APA | Zhong, Sheng,Qie, Shuai,Yang, Liu,Yan, Qi,Ge, Linna,&Wang, Zhongfeng.(2017).S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials.MEDICINE,96(30). |
| MLA | Zhong, Sheng,et al."S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials".MEDICINE 96.30(2017). |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论